Bellicum: FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

 Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer.

Bellicum worked diligently with the FDA over the past two months to respond to the clinical hold and has been informed by FDA that the company has satisfactorily addressed all clinical hold issues. Bellicum may now resume enrollment without modification to the current study protocol. The company plans to work with clinical investigators to resume patient enrollment.

https://www.streetinsider.com/Corporate+News/Bellicum+Pharma+%28BLCM%29+Reports+FDA+Lifted+Clinical+Hold+on+BPX-601+Phase+12+Clinical+Trial/17881371.html